A new paradigm for drug development and patient therapeutic strategies is required, especially for complex, heterogeneous diseases including metabolic dysfunction-associated steatotic liver disease (MASLD). Heterogeneity in MASLD patients is driven by genetics... ...

请注册登录后继续浏览